Group 1 - The company Shanghai Aike Baifa Biopharmaceutical Technology Co., Ltd. has applied for a "Type II meeting" with the CDE, which is currently in processing status [1] - Type II meetings are typically held within 60 days after application and are focused on critical issues during drug development, including pre-clinical trial meetings and risk assessment meetings [1] - The company was established in 2014 and is based in Shanghai, with a registered capital of 2,297.7284 million RMB [1] Group 2 - The company has made one external investment and holds 62 trademark registrations and 21 patents, along with 11 administrative licenses [1] - Major shareholders include Profits Excel Holdings Limited (19.5777%), Yao Yang Biotechnology Co., Ltd. (7.5115%), and Golden Trend Investment Limited (6.6427%) among others [2]
上海爱科百发生物医药技术股份有限公司申请II类会议
Sou Hu Cai Jing·2025-08-14 22:25